Möchten Sie immer auf dem neuesten Stand bleiben?

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE...

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque...

Washington, DC, March 19, 2026 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA), as well as leading allergy medical societies the American Academy of Allergy,...

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at AAD 2026

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16,...

Vanish DrySerum nanofiber acne mask claims evaluated: barrier repair technology, ingredient research, & what consumers should verify before buying in 2026.

Whispeara "brain mute button" tinnitus claims examined. 2026 consumer report on ingredient research, neural signaling theory, and hearing support.

Serious adverse effects by mRNA vaccines on immune, neurological, and endocrine functions of the skin are underrated despite warning signals.

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data in Pediatric Dermatology

WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...